Abstract
BIMT 17 (1-[2-[4-(3-trifluoromethyl phenyl) piperazin-1-yl] ethyl] benzimidazol- [1H]-2-one), a 5-HT1A receptor agonist/5-HT2A receptor antagonist (see Borsini et al., accompanying paper), in a dose range of 1-10 mg/kg i.v., dose-dependently inhibited the electrical activity of rat medial prefronto-cortical neurons, whereas buspirone, in a dose range of 0.1-1000 micrograms/kg, increased it. 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and 1-[2-(2-thenoylamino)ethyl]-4-[1-(7-methoxynaphthyl)] piperazine (S 14671) presented biphasic patterns of response; they increased electrical activity at doses in the range of 0.1-10 micrograms/kg and 0.1-3 micrograms/kg i.v. respectively, and reduced it at high doses, 30-300 micrograms/kg and 10-30 micrograms/kg i.v., respectively. The inhibitory effect of BIMT 17 on the firing rate of neurons in the frontal cortex was antagonized by the 5-HT1A antagonists tertatolol and WAY 100135, and was still present after destruction of serotonin (5-HT) containing neuronal endings by the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT; 150 micrograms/rat, given intraventricularly), which reduced the cortical 5-HT content by 85%. This destruction of 5-HT neurons, while suppressing the ability of 8-OH-D...Continue Reading
Citations
Apr 28, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Boris FergerBernd Sommer
Dec 8, 2011·Psychopharmacology·Laia Lladó-PelfortPau Celada
May 3, 1996·Neuroscience Letters·E SeifritzJ C Gillin
Jan 5, 2002·European Journal of Pharmacology·F Borsini, R Cesana
Apr 16, 1998·European Journal of Pharmacology·P D'AquilaP Willner
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·F BorsiniN Pitsikas
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A BrambillaF Borsini
Jan 22, 2013·ACS Chemical Neuroscience·Stefanie C AltieriAnne M Andrews
Apr 3, 1999·British Journal of Pharmacology·L E Rueter, P Blier
Jun 18, 1999·British Journal of Pharmacology·M HajósT Sharp
Dec 5, 2013·Neuroscience and Biobehavioral Reviews·Ian MaharJosé N Nobrega
Jun 13, 2013·CNS Drugs·Pau CeladaFrancesc Artigas
Nov 19, 2013·Pharmacology, Biochemistry, and Behavior·Lynda Uphouse
Feb 25, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Qiaojun ZhangJian Liu
Feb 3, 2016·The Journal of Sexual Medicine·Matthew F LazenkaS Stevens Negus
Dec 5, 2015·The Journal of Sexual Medicine·Alexander K ConverseDavid H Abbott
May 21, 2009·The Journal of Sexual Medicine·James G Pfaus
Feb 7, 2012·The Journal of Sexual Medicine·Yves AubertDavid H Abbott
Feb 19, 2010·The Journal of Sexual Medicine·Kelly A AllersBernd Sommer
Sep 16, 2010·The Journal of Sexual Medicine·Stephen M StahlKelly A Allers
Apr 29, 2008·Neuroscience and Biobehavioral Reviews·Andrew Holmes
Oct 2, 1998·Biological Psychiatry·P Blier, C de Montigny
Jun 26, 2010·Neuroscience·Z H GuiL L Fan
Jun 26, 2012·Psychoneuroendocrinology·Yves AubertDavid H Abbott
Nov 13, 2007·Trends in Pharmacological Sciences·Trevor SharpPhilip Quérée
Jul 24, 2010·British Journal of Pharmacology·L Lladó-PelfortP Celada